Aurinia Pharmaceuticals Inc Asset Resilience Ratio
Aurinia Pharmaceuticals Inc asset resilience ratio. Aurinia Pharmaceuticals Inc (AUPH) has an Asset Resilience Ratio of 33.23% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Aurinia Pharmaceuticals Inc (AUPH) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Aurinia Pharmaceuticals Inc (2000–2025)
Asset resilience ratio of Aurinia Pharmaceuticals Inc from 2000 to 2025. This chart shows how Aurinia Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read how much debt does Aurinia Pharmaceuticals Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Aurinia Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Aurinia Pharmaceuticals Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $263.29 Million | 33.23% |
| Total Liquid Assets | $263.29 Million | 33.23% |
Asset Resilience Insights
- Very High Liquidity: Aurinia Pharmaceuticals Inc maintains exceptional liquid asset reserves at 33.23% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aurinia Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Aurinia Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Aurinia Pharmaceuticals Inc Asset Resilience Ratio by Year (2000–2025)
Aurinia Pharmaceuticals Inc asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Aurinia Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 42.28% | $317.78 Million | $751.59 Million | -7.67pp |
| 2024-12-31 | 49.95% | $275.04 Million | $550.64 Million | -5.08pp |
| 2023-12-31 | 55.03% | $301.61 Million | $548.06 Million | -7.66pp |
| 2022-12-31 | 62.70% | $295.22 Million | $470.86 Million | +19.60pp |
| 2021-12-31 | 43.10% | $234.18 Million | $543.37 Million | +15.93pp |
| 2020-12-31 | 27.17% | $125.98 Million | $463.66 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $324.30 Million | -- |
| 2018-12-31 | 5.41% | $7.89 Million | $145.86 Million | +1.28pp |
| 2017-12-31 | 4.13% | $7.83 Million | $189.85 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $57.00 Million | -- |
| 2015-12-31 | 29.78% | $10.00 Million | $33.57 Million | +10.69pp |
| 2014-12-31 | 19.09% | $10.00 Million | $52.38 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $23.14 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $4.16 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $14.32 Million | -- |
| 2010-12-31 | 0.00% | $0.00 | $10.28 Million | -- |
| 2009-12-31 | 0.00% | $0.00 | $9.55 Million | -- |
| 2008-12-31 | 0.00% | $0.00 | $26.66 Million | -- |
| 2007-12-31 | 0.00% | $0.00 | $42.67 Million | -- |
| 2006-12-31 | 28.49% | $8.73 Million | $30.64 Million | -24.46pp |
| 2005-12-31 | 52.95% | $28.78 Million | $54.35 Million | -4.60pp |
| 2004-12-31 | 57.55% | $35.21 Million | $61.17 Million | +10.23pp |
| 2003-12-31 | 47.33% | $35.23 Million | $74.43 Million | +6.02pp |
| 2002-12-31 | 41.30% | $20.93 Million | $50.68 Million | +34.12pp |
| 2001-12-31 | 7.18% | $2.66 Million | $37.06 Million | -39.14pp |
| 2000-12-31 | 46.32% | $6.47 Million | $13.97 Million | -- |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and … Read more